We have recently investigated the possibility that transfect of the tumor suppressor gene TUSC2 in NSCLC cells deficient of its expression, could potentiate sensitivity to small-molecule targeted cancer therapy. The gene discussed is TUSC2; the disease is non-small cell lung carcinoma.